arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Bio Essence Corp

BIOE

— Price unavailable

7 Visible periods

31 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Good

Moderately Bullish

auto_awesome

Analytical Summary

Bio Essence Corp demonstrates solid fundamentals with strength in Profit Margin (%). However, watch Return on Common Equity (%) which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap —

Dividend Yield —

Revenue Growth 485.8% ↗

Op. Margin 47.4% ↗

ROIC -44.6% ↘

FCF / Share $0.04 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity -0.03

info Valuation on last close.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$1.90M

↑ +485.8% —

Net Income Profit after all expenses

$896.20K

↑ +168.5% —

Operating Margin Operating profit as % of sales

47.4%

↑ +133.4% 96th

FCF / Share Free cash flow per share

$0.04

↑ +151.6% —

Long-Term Debt Long-term obligations

$57.48K

↑ +1.8% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)
Operating Margin (%)Operating Margin (%) is in the top quartile
Profit Margin (%)Profit Margin (%) is in the top quartile

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability

Returns

Financial Health ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	485.8% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+5972%)	-41.3% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-616%)	-11.3% Weak ↑ Weak Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-241%)	-30.0% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-475%)	-7.4% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-192%)	—	—
EPS Growth YoY (%)	—	-50.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	N/M	-34.7% Weak ↓ Weak Declining Year-over-year change in net income	-20.0% Weak ↓ Weak Declining Year-over-year change in net income	-25.0% Weak Weak Year-over-year change in net income	-8.7% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	151.6% Excellent Excellent Year-over-year change in free cash flow	N/M	-33.7% Weak Weak Year-over-year change in free cash flow	—	—	—	—
Revenue CAGR 3Y (%)	45.1% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-28.5% Weak Weak Compound annual revenue growth over 3 years	-16.8% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	14.6% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	47.4% Excellent ↑ Excellent Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+216%)	-141.8% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1046%)	-143.1% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1054%)	-82.2% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-648%)	-96.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-744%)	-86.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-679%)	—
Effective Tax Rate (%) (%)	0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.3% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.5% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.5% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.6% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	47.2% Excellent ↑ Excellent Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+294%)	-404.0% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3467%)	-176.2% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1569%)	-130.3% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1185%)	-72.9% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-708%)	-62.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-618%)	—
FCF Margin (%) (%)	82.7% Excellent ↑ Excellent Improving Free cash flow as a percentage of revenue Optimal: > 10%	192.6% Excellent ↑ Excellent Improving Free cash flow as a percentage of revenue Optimal: > 10%	-186.6% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-113.7% Weak → Weak Stable Free cash flow as a percentage of revenue Optimal: > 10%	-159.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-77.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	1.75x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	-0.48x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.06x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	2.18x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	1.24x Good Good Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-44.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	15.8% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	47.7% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	15.9% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	35.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	47.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	213.0% Excellent ↑ Excellent Improving Operating profit relative to total assets Optimal: > 10%	-163.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-29.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-33.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-50.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-45.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-43.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-388%)	44.1% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+194%)	58.5% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+290%)	25.0% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+67%)	26.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+78%)	33.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+123%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Debt to Equity (x)	-0.03x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-105%)	-0.02x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-103%)	—	—	—	—	—
Interest Coverage (x)	411.72x Excellent ↑ Excellent Improving Operating income divided by interest expense Optimal: > 5x	-72.85x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-45.49x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-36.17x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-22.24x Weak Weak Operating income divided by interest expense Optimal: > 5x	-19.87x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$57.48K	$55.11K	$-114.00	$-6.26K	$-303.00	$-5.33K	$-16.16K
Debt / EBITDA (x)	0.06x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.12x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$0.05	$0.01	$0.02	$0.02	—	—	—
Basic EPS, GAAP (USD)	—	$-0.03	$-0.02	$-0.02	—	—	—
Free Cash Flow per Share (USD)	$0.04	$0.02	$-0.03	$-0.02	—	—	—
Book Value per Share (USD)	$-0.05	$-0.08	$-0.04	$-0.10	$-0.07	$-0.05	—
Tangible Book Value per Share (USD)	$-0.05	$-0.08	$-0.04	$-0.10	$-0.07	$-0.05	—
Basic Weighted Avg Shares (shares)	38.01M	38.01M	35.95M	33.01M	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$-2.02M	$-2.52M	$-2.08M	$-3.35M	$-2.49M	$-1.57M	—
LT Debt (USD)	$57.48K	$56.48K	—	—	—	—	—
Total Equity (USD)	$-2.07M	$-2.97M	$-1.66M	$-3.24M	$-2.43M	$-1.78M	$-1.09M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$1.90M	$323.94K	$551.51K	$621.59K	$887.98K	$958.70K	—
Depreciation Expense (USD)	—	$911.00	$17.42K	$14.51K	$29.45K	$22.56K	—
Net Income, GAAP (USD)	$896.20K	$-1.31M	$-971.88K	$-809.68K	$-647.56K	$-595.84K	—
Operating Cash Flow (USD)	$1.57M	$623.87K	$-1.03M	$-703.24K	$-1.29M	$-732.74K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters

Bio Essence Corp

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BIOE with peers